Glaukos subsequently advanced a second-generation treatment, Epioxa, through phase III trials. SanaCurrents assigns a pivolat probability Glaukos will submit an NDA for Epioxa in 2022.
In March, we’ve already received two premium member contributions – one from Andrew Ing (@AndrewIng8) on a stock based in Australia, which is a first for our community, and another from Tim Heitman (@Investing501), who regularly published articles to GeoInvesting in 2021. We’d like to extend a thank you to them for choosing GeoInvesting as the platform to share their ideas for all of us to appreciate.